The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.